source
- FDA rejects ITM's radiopharma drug for neuroendocrine tumors over manufacturing issuesThe U.S. Food and Drug Administration has refused to approve a radiopharmaceutical candidate from ITM Isotope Technologies Munich intended for treating neuroendocrine tumors. The agency cited manu…
- Bristol Myers Squibb announces $2.3 billion manufacturing campus in HoustonBristol Myers Squibb disclosed plans to build a new manufacturing campus in Houston, Texas, with an estimated cost of $2.3 billion. The campus will expand the company's domestic production capacit…